Search company, investor...

Founded Year




Total Raised


Date of IPO


Market Cap


Stock Price


About LianBio

LianBio (NASDAQ: LIAN) operates as a biotechnology company with a focus on the development and distribution of medicines. The company's main offerings include the development of transformative and precision-based therapeutics in areas such as cardiovascular, oncology, ophthalmology, and inflammatory disease. LianBio primarily serves the healthcare industry. It was founded in 2020 and is based in Shanghai, China.

Headquarters Location

9th Floor, Kerry Parkside, 1155 Fangdian Road Unit 901-902

Shanghai, Shanghai, 201204,




Latest LianBio News

LianBio GAAP EPS of -$0.22 beats by $0.06

Nov 14, 2023

Nov. 14, 2023 2:09 AM ET LianBio (LIAN) By: Pranav Ghumatkar , SA News Editor LianBio press release (NASDAQ: LIAN ): Q3 GAAP EPS of -$0.22 beats by $0.06. Cash, cash equivalents, marketable securities and restricted cash at September 30, 2023 totaled $252.2 million compared to $302.4 million as of December 31, 2022. More on LianBio

LianBio Frequently Asked Questions (FAQ)

  • When was LianBio founded?

    LianBio was founded in 2020.

  • Where is LianBio's headquarters?

    LianBio's headquarters is located at 9th Floor, Kerry Parkside, 1155 Fangdian Road Unit 901-902, Shanghai.

  • What is LianBio's latest funding round?

    LianBio's latest funding round is IPO.

  • How much did LianBio raise?

    LianBio raised a total of $310M.

  • Who are the investors of LianBio?

    Investors of LianBio include Perceptive Advisors, Vida Ventures, Farallon Capital Management, Pfizer, Viking Global Investors and 12 more.



CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.